Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer
In Partnership With:
Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.
Chau T. Dang, MD, medical oncologist, the Regional Care Network Medical Site Director,Memorial Sloan Kettering Westchester, discusses the rationale of the phase 2 BERENICE trial (NCT02132949) in early-stage HER2-positive breast cancer.
The BERENICE trial was a multicenter, 2-cohort study that utilized the primary end of cardiac safety, Dang says. Patients in cohort A received dose-dense anthracycline-based chemotherapy followed by pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel, Dang explains. In cohort B, patients received 5-fluorouracil, epirubicin, and cyclophosphamide, followed by docetaxel, trastuzumab, and pertuzumab, Dang says.
Moreover, the secondary end points of the study included total pathologic complete response rate, event-free survival, invasive disease-free survival, and overall survival, Dang concludes.
